Palicitexal Auro 30 mg/5 ml ,100 mg/ 67 ml ,150 mg / 25 ml and 300 mg/ 50 ml Injection
PDF Leaflet Revision Date: N/A
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced ovarian and breast cancer.
Dosage (summary)
175 mg/m2 IV over 3 hours every 3 weeks; adjust for neutropenia.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; avoid breastfeeding during treatment.
Key Drug Interactions
- Cisplatin
- Doxorubicin
- CYP2C8 and CYP3A4 inhibitors
Contraindications
- Severe hypersensitivity to paclitaxel
- Baseline neutrophil count <1500 cells/mm3
Common side effects
- Neutropenia
- Peripheral neuropathy
- Hypersensitivity reactions
Counselling Points
- Premedicate with corticosteroids and antihistamines
- Monitor blood counts regularly
- Avoid pregnancy during treatment
Serious warnings
- Severe hypersensitivity reactions
- Bone marrow suppression
- Cardiac conduction abnormalities
Important Disclaimer
The Palicitexal Auro 30 mg/5 ml ,100 mg/ 67 ml ,150 mg / 25 ml and 300 mg/ 50 ml Injection professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
